498 related articles for article (PubMed ID: 32503171)
1. Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art.
Shetab Boushehri MA; Dietrich D; Lamprecht A
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32503171
[TBL] [Abstract][Full Text] [Related]
2. Advances of paclitaxel formulations based on nanosystem delivery technology.
Luo C; Wang Y; Chen Q; Han X; Liu X; Sun J; He Z
Mini Rev Med Chem; 2012 May; 12(5):434-44. PubMed ID: 22303950
[TBL] [Abstract][Full Text] [Related]
3. Current approaches for in vitro drug release study of long acting parenteral formulations.
Dadhaniya TM; Sharma OP; Gohel MC; Mehta PJ
Curr Drug Deliv; 2015; 12(3):256-70. PubMed ID: 25666683
[TBL] [Abstract][Full Text] [Related]
4. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
5. Controlled-release injectable microemulsions: recent advances and potential opportunities.
Dubey R
Expert Opin Drug Deliv; 2014 Feb; 11(2):159-73. PubMed ID: 24328888
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Screening Methods To Assess the Potential of In Vivo Precipitation of Injectable Formulations upon Intravenous Administration.
Sheth AR
PDA J Pharm Sci Technol; 2011; 65(1):71-80. PubMed ID: 21414942
[TBL] [Abstract][Full Text] [Related]
7. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
[TBL] [Abstract][Full Text] [Related]
8. Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.
Bakrania AK; Variya BC; Patel SS
Pharmacol Res; 2016 Sep; 111():577-591. PubMed ID: 27461138
[TBL] [Abstract][Full Text] [Related]
9. Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.
Zheng N; Sun DD; Zou P; Jiang W
AAPS J; 2017 May; 19(3):619-631. PubMed ID: 28116676
[TBL] [Abstract][Full Text] [Related]
10. Nanosize drug delivery system.
Mukherjee B
Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery systems with modified release for systemic and biophase bioavailability.
Leucuta SE
Curr Clin Pharmacol; 2012 Nov; 7(4):282-317. PubMed ID: 22794159
[TBL] [Abstract][Full Text] [Related]
12. [Overview of Analytical Techniques for Evaluation of Nano-DDS Formulations].
Sakai-Kato K
Yakugaku Zasshi; 2019; 139(2):255-260. PubMed ID: 30713236
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology and Microtechnology in Drug Delivery Systems.
Sun J; Yang Z; Teng L
Dose Response; 2020; 18(2):1559325820907810. PubMed ID: 32313522
[TBL] [Abstract][Full Text] [Related]
14. Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery.
Bajracharya R; Song JG; Back SY; Han HK
Comput Struct Biotechnol J; 2019; 17():1290-1308. PubMed ID: 31921395
[TBL] [Abstract][Full Text] [Related]
15. Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses.
Siafaka PI; Üstündağ Okur N; Karavas E; Bikiaris DN
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589733
[TBL] [Abstract][Full Text] [Related]
16. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P; Subramony JA
J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges.
Pozharov VP; Minko T
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678823
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the engineering of nanosized active pharmaceutical ingredients: Promises and challenges.
Kaialy W; Al Shafiee M
Adv Colloid Interface Sci; 2016 Feb; 228():71-91. PubMed ID: 26792017
[TBL] [Abstract][Full Text] [Related]
19. Medical contraindications and issues for consideration in the use of once-a-month injectable contraceptives.
Dorflinger LJ
Contraception; 1994 May; 49(5):455-68. PubMed ID: 8045132
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
